Lim Y-S. et al. Long term safety profile of tenofovir alafenamide in chronic hepatitis B patients; final 8-year results of 2 phase 3 studies

Zurück zur Übersicht

21.-24.06.2023 / EASL

Studiensammlung zu Lebererkrankungen

Lampertico P. et al. Continued Treatment of Early Nonresponders or Partial Virologic Responders With Bulevirtide Monotherapy in Patients With Chronic Hepatitis Delta Through Week 96 Leads to Improvement in Virologic and Biochemical Responses

21.-24.06.2023 / EASL

Lebererkrankungen

Esteban R. et al. Concomitant use of Proton Pump Inhibitors and Sofosbuvir/Velpatasvir: Evidence from Randomized Clinical trials and Real-World Data

21.-24.06.2023 / EASL

Lebererkrankungen

Sokal, M. E. et al: Safety and Efficacy of Sofosbuvir/Velpatasvir for the Treatment of Chronic Hepatitis C Infection in Children and Adolescents Aged 3 to 17 Years Old Through 24 Weeks Posttreatment

13.-16.11.2020 / AASLD

Lebererkrankungen

Higher incidence of hepatocellular carcinoma in patients with cirrhosis caused by HBV-HDV co- 1nfection compared to HBV mono-infection

12.-15.11.2021 / AASLD

Lebererkrankungen

Wedemeyer, H. et al: Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

22.-26.06.2022 / EASL ILC

Lebererkrankungen

Loglio, A. et al: Early clinical and virological changes in HDV patients with advanced cirrhosis treated with bulevirtide montherapy in a real life setting

12.-15.11.2021 / AASLD

Lebererkrankungen

Wedemeyer H. et al. Bulevirtide Monotherapy at Low and High Doses in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study

23.-26.06.2021 / EASL 2021

Lebererkrankungen

Asselah T. et al. Safety and Efficacy of BulevirtideMonotherapy and in Combination with Peginterferon Alfa-2a in Patients with Chronic Hepatitis Delta:24 Weeks Interim Data of MYR204 Phase 2b Study

23.-26.06.2021 / EASL 2021

Lebererkrankungen